Erektil disfonksiyonda intrakavernozal self enjeksiyon: Hasta uyumu ve etkinliği

Abstract

Amaç: Bu klinik çalışmada; erektil disfonksiyonlu olgularda intrakavernozal tedavinin etkinliği ve olguların tedaviye uyumu araştırıldı.Gereç ve Yöntemler: Haziran 2003 – Temmuz 2011 tarihleri arasında erektil disfonksiyon nedeni ile intrakavernozal tedavi alan yaşları 23 ile 77 arasında değişen 52 olgu değerlendirildi. Değerlendirme; etyoloji, hasta memnuniyeti, ereksiyon süresi, ereksiyon kalitesi, hasta uyumu, komplikasyonlar ve tedaviyi terk etme kriterleri ile yapıldı.Bulgular: Erektil disfonksiyon etyolojisi 19 olguda vasküler, 11 olguda psikojenik, 15 olguda nörojenik, 4 olguda mix, 3 olguda ise idyopatikti. Yaşlı hastalarda elde edilen rijidite oranı daha düşük, tedaviyi sürdürme ve hasta memnuniyeti daha yüksekti. Genç hastalarda rijidite yüksek olmakla birlikte tedaviyi terk etme oranı yaşlı hastalara göre daha yüksekti. En iyi cevap nörojenik ve psikojenik grupta elde edildi. Cevap oranları sırası ile Psikojenik grupta % 82 nörojenik grupta %80, vasküler grupta %73,7, mix grupta %75, idyopatik grupta %67 idi. 7 olguda ekimoz, 4 olguda priapismus, 2 olguda fibrozis gelişti. Sonuç: İntrakavernozal self enjeksiyon, etkili ve tatminkâr ereksiyon sağlamaktadır. Özellikle yaşlı hasta grubunda tedavinin sürdürülebilirliği daha yüksektir

Keywords

• Erektil disfonksiyon,intrakavernozal tedavi,papaverin,fentolamin

Intracavernosal self injection in erectile dysfunction: Patient compliance and effectiveness

Abstract

Objective: The purpose of this clinical study is to investigate the efficacy of intracavernous therapy, and compliance of patients with erectile dysfunction.Material and Methods: From June 2003 to July 2011, 52 cases of patients within the age group of 23–77, receiving intracavernous treatment for erectile dysfunction were evaluated. Criteria for evaluation: Patient satisfaction, duration of erection, quality of erection, patient compliance, complications, abandonment of treatment.Results: 19 cases were Vascular, 11 were psychogenic, 15 were neurogenic, 4 were mixed, and 3 were idiopathic. The rate of rigidity in elderly patients was lower, continuation of treatment and patient satisfaction were higher. In younger patients, although the rate of rigidity was higher, the rate of treatment abandonment was higher as well when compared to elderly patients. The best response was obtained in psychogenic and neurogenic group. Response rates for psychogenic, neurogenic, vascular, mixed and idiopathic groups were, 82%, 80%, 73,7%, 75% and 67% respectively. 7 patients had ecchymosis, 4 had priapism, and 2 had fibrosis.Conclusion: Intracavernosal self-injection provides an effective and satisfactory erection. The sustainability of treatment, especially in elderly patients is higher

Keywords

• Erectile dysfunction,intracavernosal therapy,papaverine,phentolamine

References

1. Akkuş E, Kadıoğlu A, Esen A, Doran Ş, Ergen A, Anafar- ta K,et al. (Turkish Erectile Dysfunction Prevalence Study Group): Prevalence and correlates of erectile dysfunction in Turkey: A Population Based Study. Eur Urol 2002; 41: 298–304.
2. Virag R. Intracavernous injection of papaverine for erecti- le failure. Lancet 1982; 2: 938.
3. Van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharma- cokinetics of vazoactive substances administered into the human corpus cavernosum. J Urol 1994; 151:1227–30.
4. Zentgraf M, Baccouche M, Jünemann KP. Diagnosis and therapy of erectile dysfunction using papaverine and phen- tolamine. Urol Int 1988; 43:65–75.
5. Stief CG, Wetterauer U. Erectile responses to intracaver- nous papaverine and phentolamine: Comparison of single and combined delivery. J Urol 1988; 140:1415–6.
6. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, et al. Side effect of self administration of intra- cavernouc papaverine end phentolamine fort he treatment of impotence. J Urol 1989; 141:54–7.
7. Chandeck Montesa K, Chen Jiménez J, Tamayo JC, Rodríguez Antolín A, Alvarez González E. Pospective study of of effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phento- lamine in the diagnosis and treatment of erection dysfunc- tion. Review of the literature. Actas Urol Esp 1992; 16: 208–216.
8. Di injection nonresponse with sildenafil alone or in com- bination with triple agent intracorporeal injection therapy. J Urol 1999; 162:1992–8.